News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
329,682 Results
Type
Article (19735)
Company Profile (140)
Press Release (309807)
Section
Business (105260)
Career Advice (875)
Deals (18515)
Drug Delivery (93)
Drug Development (50691)
Employer Resources (79)
FDA (7655)
Job Trends (7732)
News (185654)
Policy (17311)
Tag
Academia (726)
Alliances (27782)
Alzheimer's disease (593)
Antibody-drug conjugate (ADC) (67)
Approvals (7639)
Artificial intelligence (97)
Bankruptcy (171)
Best Places to Work (5547)
Biosimilars (72)
Breast cancer (88)
Cancer (772)
Cardiovascular disease (77)
Career advice (708)
Cell therapy (113)
Clinical research (42135)
Collaboration (320)
Compensation (106)
COVID-19 (1081)
C-suite (88)
Data (804)
Diabetes (113)
Diagnostics (1732)
Drug pricing (100)
Earnings (38375)
Employer resources (73)
Events (47953)
Executive appointments (308)
FDA (8034)
Funding (226)
Gene therapy (105)
GLP-1 (527)
Government (1809)
Healthcare (5879)
Infectious disease (1141)
Inflammatory bowel disease (74)
Interviews (115)
IPO (7332)
Job creations (2431)
Job search strategy (646)
Layoffs (259)
Legal (4086)
Lung cancer (122)
Manufacturing (153)
Medical device (1952)
Medtech (1955)
Mergers & acquisitions (11310)
Metabolic disorders (386)
Neuroscience (810)
NextGen: Class of 2025 (2352)
Non-profit (904)
Northern California (829)
Obesity (248)
Opinion (179)
Patents (90)
People (33118)
Pharmaceutical (78)
Phase I (13170)
Phase II (17824)
Phase III (14338)
Pipeline (379)
Policy (78)
Postmarket research (1617)
Preclinical (4595)
Radiopharmaceuticals (157)
Rare diseases (175)
Real estate (3168)
Regulatory (12280)
Research institute (816)
Resumes & cover letters (138)
Southern California (763)
Startups (2006)
United States (7570)
Vaccines (225)
Weight loss (207)
Date
Today (68)
Last 7 days (202)
Last 30 days (973)
Last 365 days (17481)
2025 (877)
2024 (17694)
2023 (19650)
2022 (25880)
2021 (26643)
2020 (24872)
2019 (20058)
2018 (15588)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14788)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (406)
Asia (24638)
Australia (3172)
California (1888)
Canada (888)
China (223)
Colorado (77)
Connecticut (77)
Europe (50809)
Florida (289)
Illinois (190)
Indiana (140)
Japan (77)
Maryland (278)
Massachusetts (1596)
Minnesota (106)
New Jersey (726)
New York (540)
North Carolina (406)
Northern California (829)
Ohio (68)
Pennsylvania (447)
South America (605)
Southern California (763)
Texas (252)
Washington State (170)
329,682 Results for "vifor pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Practices
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
April 22, 2024
·
2 min read
·
Tristan Manalac
Press Releases
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
October 17, 2024
·
4 min read
Policy
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day.
April 24, 2024
·
7 min read
Press Releases
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024
·
14 min read
Policy
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Travere Therapeutics, Inc., and CSL Vifor announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day.
April 24, 2024
·
16 min read
China
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
January 7, 2025
·
6 min read
·
Annalee Armstrong
Policy
Approval of delisting of Vifor Pharma AG’s registered shares
Vifor Pharma AG announced that Vifor has received approval for the delisting of the totality of Vifor’s registered shares.
October 12, 2022
·
3 min read
Biotech Beach
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
CSL Vifor and Travere Therapeutics, Inc., announced that the European Medicines Agency’s CHMP has recommended approval of sparsentan for the treatment of adults with primary IgAN with a urine protein excretion >1.0 g/day. IgAN is a rare kidney disorder and a leading cause of kidney failure.
February 23, 2024
·
5 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Vifor Pharma AG announced that the Commercial Court St. Gallen has cancelled all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each.
December 14, 2022
·
3 min read
1 of 32,969
Next
